Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events

BACKGROUND: Some rheumatoid arthritis (RA) patients initially respond to treatment with infliximab (IFX), but subsequently their responsiveness decreases. OBJECTIVES: Our objective was to evaluate the efficacy and safety of switching from IFX to subcutaneous golimumab (GLM-SC) in RA patients. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakabayashi, Hiroki, Inada, Hitoshi, Nishioka, Yosuke, Hasegawa, Masahiro, Nishioka, Kusuki, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318330/
https://www.ncbi.nlm.nih.gov/pubmed/28025727
http://dx.doi.org/10.1007/s40268-016-0162-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318330/
https://www.ncbi.nlm.nih.gov/pubmed/28025727
http://dx.doi.org/10.1007/s40268-016-0162-8

Ejemplares similares